Significance of serum APE1-AAbs, PTX-3, and miR-486-3p in patients with colorectal cancer undergoing radical surgery

Table 2 Comparison of clinical data, n (%)

	Occurrence (n = 28)	Non-occurrence (n = 126)	t/χ2	P value
Age, years			6.464	0.011
< 60	13 (46.43)	90 (71.43)
≥ 60	15 (53.57)	36 (28.57)
Gender			0.023	0.877
Male	16 (57.14)	74 (58.73)
Female	12 (42.86)	52 (41.27)
Comorbidities
Hypertension	12 (42.86)	47 (37.30)	0.299	0.584
Hyperlipidemia	11 (39.29)	39 (30.95)	0.726	0.394
Diabetes	8 (28.57)	31 (24.60)	0.190	0.662
BMI (kg/m²)	24.83 ± 1.34	24.56 ± 1.37	0.946	0.345
Tumor growth pattern			0.713	0.398
Infiltrative	23 (82.14)	94 (74.60)
Expansive or others	5 (17.86)	32 (25.40)
Lymph node metastasis			6.086	0.013
Yes	12 (42.86)	26 (20.63)
No	16 (57.14)	100 (79.37)
TNM pathological stage			6.002	0.014
Stages I-II	13 (46.43)	89 (70.63)
Stage III	15 (53.57)	37 (29.37)
Tumor differentiation type			4.757	0.029
Low differentiation	16 (57.14)	44 (34.92)
Moderate-high differentiation	12 (42.86)	82 (65.08)
Vascular invasion			0.151	0.696
Yes	10 (35.71)	50 (39.68)
No	18 (64.29)	76 (60.32)
Nerve invasion			0.119	0.729
Yes	11 (39.29)	54 (42.86)
No	17 (60.71)	72 (57.14)
Tumor location			0.058	0.895
Colon	10 (35.71)	42 (33.33)
Rectum	18 (64.29)	84 (66.67)
Tumor diameter, cm			5.147	0.023
< 5	13 (46.43)	87 (69.05)
≥ 5	15 (53.57)	39 (30.95)
Chemotherapy			0.515	0.472
Yes	20 (71.43)	98 (77.78)
No	8 (28.57)	28 (22.22)
PT (× 109/L)	225.54 ± 29.87	185.96 ± 20.73	8.373	< 0.001
WBC (× 109/L)	5.87 ± 1.72	5.73 ± 1.69	0.395	0.693
CEA (ng/mL)	16.45 ± 4.29	13.06 ± 3.25	4.692	< 0.001
CA19-9 (U/mL)	75.48 ± 7.87	58.31 ± 6.14	12.680	< 0.001

BMI: Body mass index; TNM: Tumor-node-metastasis; PT: Platelet count; WBC: White blood cell count; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.